~10K
patients analysed in MDV
In multiple myeloma, novel therapies are increasingly being incorporated into clinical practice. Despite these treatment advancements, there is a lack of comprehensive real-world evidence (RWE) regarding how these changes have impacted patient management. This retrospective observational study used the Medical Data Vision (MDV) database to characterise treatment patterns for patients with multiple myeloma in Japan. As such, this study aimed to:
This study employed a retrospective observational cohort approach leveraging data from the MDV database to analyse treatment patterns in multiple myeloma patients in Japan. MDV is a commercially available health administrative database containing 39 million patients’ inpatient and outpatient data from approximately 26% of advanced treatment hospitals using the diagnosis procedure combination (DPC) payment system in Japan. For this study, the cohort included 9,679 patients who were diagnosed with multiple myeloma from 2016 onwards. The analysis involved characterising baseline patient demographics and clinical features, identifying distinct lines of treatment using an algorithmic approach, and summarising the frequency of various drug regimens by name and class. Additionally, the study estimated the time to next treatment between lines of treatment through Kaplan-Meier survival analyses. Preliminary observations suggested a significant shift from proteasome inhibitors to immunomodulatory imide drugs and monoclonal antibodies, with median time to next treatment decreasing in later treatment lines.
This study demonstrated an evolving treatment landscape for multiple myeloma in Japan. Observations suggested a significant shift from proteasome inhibitors, which have been long considered the backbone of treatment, to immunomodulatory imide drugs and monoclonal antibodies. Furthermore, time-to-next treatment in later lines of therapy was decreased, suggesting more frequent treatment switching with the advent of additional therapeutic options.
This study represents a large database study of insurance claims from multiple myeloma patients in Japan, providing real-world perspective of the changing treatment landscape within this population, particularly the sequence of regimen combinations used in local practice.
Costello Medical conducted an efficient analyses of the database, adapting published algorithms where possible to deliver a timely and cost-effective study. As this study better characterises the treatment landscape for patients with multiple myeloma in Japan, it provides valuable insights that could inform healthcare providers, policymakers, and researchers, ultimately guiding the optimisation of multiple myeloma management in Japan.
We have a wealth of experience designing and conducting analyses of secondary datasets and patient registries to answer a variety of research questions including healthcare resource utilisation, treatment patterns, burden of disease and treatment effectiveness. We work closely with clients to deliver on their RWE strategy. To find out more about our research or to discuss a future collaboration, please get in touch.
Looking for something specific? Search our case studies here.
